Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bengt Kull

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 21, 2010
Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screeningFabrizio Giordanetto, Bengt Kull, Anita Dellsén
Kidney International|September 22, 2023
The authors replyFernanda Florez-Barros, Siobhan Bearder, Bengt Kull, et al.
Kidney International|September 26, 2022
Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protectiveFernanda Florez-Barros, Siobhan Bearder, Bengt Kull, et al.
ESC Heart Failure|May 20, 2020
Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patientsCamilla Hage, Erik Michaëlsson, Bengt Kull, et al.
Cell Reports|April 4, 2019
Mature Human White Adipocytes Cultured under Membranes Maintain Identity, Function, and Can Transdifferentiate into Brown-like AdipocytesMatthew J Harms, Qian Li, Sunjae Lee, et al.
Journal of Medicinal Chemistry|October 3, 2022
Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction"Tord Inghardt, Thomas Antonsson, Cecilia Ericsson, et al.
Journal of Medicinal Chemistry|August 25, 2022
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection FractionTord Inghardt, Thomas Antonsson, Cecilia Ericsson, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 22, 2023
Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional ExtensionsMuhammad Nawaz, Sepideh Heydarkhan-Hagvall, Benyapa Tangruksa, et al.
Diabetes|December 29, 2022
Elevated Adipocyte Membrane Phospholipid Saturation Does Not Compromise Insulin SignalingHenrik Palmgren, Kasparas Petkevicius, Stefano Bartesaghi, et al.
Circulation|June 17, 2024
Novel Mouse Model of Myocardial Infarction, Plaque Rupture, and Stroke Shows Improved Survival With Myeloperoxidase InhibitionSohel Shamsuzzaman, Rebecca A Deaton, Anita Salamon, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry Letters|December 21, 2010
Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screeningFabrizio Giordanetto, Bengt Kull, Anita Dellsén
Kidney International|September 22, 2023
The authors replyFernanda Florez-Barros, Siobhan Bearder, Bengt Kull, et al.
Kidney International|September 26, 2022
Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protectiveFernanda Florez-Barros, Siobhan Bearder, Bengt Kull, et al.
ESC Heart Failure|May 20, 2020
Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patientsCamilla Hage, Erik Michaëlsson, Bengt Kull, et al.
Cell Reports|April 4, 2019
Mature Human White Adipocytes Cultured under Membranes Maintain Identity, Function, and Can Transdifferentiate into Brown-like AdipocytesMatthew J Harms, Qian Li, Sunjae Lee, et al.
Journal of Medicinal Chemistry|October 3, 2022
Correction to "Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction"Tord Inghardt, Thomas Antonsson, Cecilia Ericsson, et al.
Journal of Medicinal Chemistry|August 25, 2022
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection FractionTord Inghardt, Thomas Antonsson, Cecilia Ericsson, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 22, 2023
Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional ExtensionsMuhammad Nawaz, Sepideh Heydarkhan-Hagvall, Benyapa Tangruksa, et al.
Diabetes|December 29, 2022
Elevated Adipocyte Membrane Phospholipid Saturation Does Not Compromise Insulin SignalingHenrik Palmgren, Kasparas Petkevicius, Stefano Bartesaghi, et al.
Circulation|June 17, 2024
Novel Mouse Model of Myocardial Infarction, Plaque Rupture, and Stroke Shows Improved Survival With Myeloperoxidase InhibitionSohel Shamsuzzaman, Rebecca A Deaton, Anita Salamon, et al.
Pageof 2